Patents by Inventor Robert L. Hunter

Robert L. Hunter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110212047
    Abstract: Methods are provided for the treatment of chronic microvascular diseases characterized by inflammation, such as age-related macular degeneration, by administering a polyoxyethylene/polyoxypropylene copolymer. Although a single dose can be effective, multiple treatments can be administered to achieve an optimal and sustained effect. Preferably, a single administration followed by repeated weekly administration of the pharmaceutical composition, but not continuous infusion, achieves a desired effect. Methods of diagnosis and characterization of chronic microvascular diseases using the copolymer are also provided.
    Type: Application
    Filed: August 11, 2008
    Publication date: September 1, 2011
    Applicant: Synth Rx, Inc.
    Inventors: Robert L. Hunter, Martin Emanuele
  • Patent number: 7926124
    Abstract: Three dimensional fabric matrices are provided for insertion into compartments of or attachment to wearable items and padded items, referred to as contact articles. The matrix includes a core that maintains an air space between inner and outer layers to facilitate heat transfer by convection and evaporation, when the enclosure is breathable. When the enclosure restricts air permeation, the air space provides insulation. Embodiments reconfigurable from insulating to breathable include adjustable impermeable sections that releasably cover permeable sections. The matrix also absorbs shocks and distributes stresses to provide padding and cushioning, including reduction of backface signature in ballistic applications. Wearable items containing one or more matrices offer enhanced thermal regulation and shock absorption.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 19, 2011
    Assignee: Variloft, LLC
    Inventors: Robert L. Hunter, Whitney R. Hunter, Stephen A. Gathings
  • Publication number: 20100186134
    Abstract: Three dimensional fabric matrices are provided for insertion into compartments of or attachment to wearable items and padded items, referred to as contact articles. The matrix includes a core that maintains an air space between inner and outer layers to facilitate heat transfer by convection and evaporation, when the enclosure is breathable. When the enclosure restricts air permeation, the air space provides insulation. Embodiments reconfigurable from insulating to breathable include adjustable impermeable sections that releasably cover permeable sections. The matrix also absorbs shocks and distributes stresses to provide padding and cushioning, including reduction of backface signature in ballistic applications. Wearable items containing one or more matrices offer enhanced thermal regulation and shock absorption.
    Type: Application
    Filed: November 17, 2009
    Publication date: July 29, 2010
    Applicant: VARILOFT, LLC
    Inventors: Robert L. Hunter, Whitney R. Hunter, Stephen A. Gathings
  • Publication number: 20100172845
    Abstract: Disclosed are compositions and improved methods for effective treatment of Mycobacterial infections in susceptible animals. Also disclosed are regimens for preventing, reducing, or ameliorating the emergence of symptoms of Mycobacterium tuberculosis infection in susceptible individuals, as well as methods for reducing the spread of tubercular infections in at-risk populations.
    Type: Application
    Filed: May 29, 2008
    Publication date: July 8, 2010
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James K. Stoops, Robert L. Hunter, Semyon A. Risin
  • Patent number: 6747064
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: June 8, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Publication number: 20020183398
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Application
    Filed: December 14, 2001
    Publication date: December 5, 2002
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 6359014
    Abstract: The present invention comprises preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: March 19, 2002
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5990241
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: November 23, 1999
    Assignee: CytRx, Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5885590
    Abstract: The present invention relates to water-in-oil and water-in-oil-in-water multiple emulsions and methods of preparation which overcome many of the limitations of previous emulsions and are superior preparations for use in numerous applications including, but not limited to, vaccine adjuvants, pharmaceuticals, cosmetics, foods, and various household and industrial uses.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: March 23, 1999
    Inventors: Robert L. Hunter, Carol Elizabeth Bennett
  • Patent number: 5811088
    Abstract: In accordance with the present invention, a composition and method is provided that is effective in treating infections caused by microorganisms including, but not limited to, bacteria, viruses, and fungi. The present invention is effective in inhibiting the growth of bacteria such as Mycobacterium species including, but not limited to, Mycobacterium avium-intracellulare complex and M. tuberculosis. The present invention comprises a surface active copolymer, preferably an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 1200 to 15,000, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.4 O) constitutes approximately 1% to 50% by weight of the compound.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 22, 1998
    Assignee: Emory University
    Inventors: Robert L. Hunter, R. Martin Emanuele, Hameedsulthan S. Allaudeen
  • Patent number: 5696298
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 9, 1997
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5691387
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: November 25, 1997
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5648071
    Abstract: In accordance with the present invention, a method is provided for treating tumors. More particularly, the present invention relates to a method for treating tumors comprising injecting a solution of certain ethylene oxide-propylene oxide surface-active copolymers and a solution containing chemotherapeutic agents into a human or animal with a tumor. The solutions can be injected simultaneously or separately at different times. In addition, the surface-active copolymer and the chemotherapeutic agent can be in the same solution. The surface-active copolymer can be an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (O.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 950 to 4000 daltons, preferably approximately 1200 to 3500 daltons, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: July 15, 1997
    Assignee: Emory University
    Inventors: Robert L. Hunter, Alexander Duncan
  • Patent number: 5622649
    Abstract: Water-in-oil and water-n-oil-in-water multiple emulsions and methods of preparation employing polyoxyethylene polyoxypropylene block copolymers added to the inner aqueous phase during preparation of said emulsions. The emulsions are useful in numerous applications including, but not limited to, vaccine adjuvants, pharmaceuticals, cosmetics, foods, and various household and industrial uses.
    Type: Grant
    Filed: August 16, 1994
    Date of Patent: April 22, 1997
    Assignee: Emory University
    Inventors: Robert L. Hunter, Carol E. Bennett
  • Patent number: 5554372
    Abstract: The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: September 10, 1996
    Assignee: Emory University
    Inventor: Robert L. Hunter
  • Patent number: 5523492
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: June 4, 1996
    Assignee: CYTRX Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: 5494660
    Abstract: A new class of biologically-active copolymers is provided capable of affecting biological systems in many different ways. The biologically-active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically-active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut. Another preferred use is treatment of surfaces to interfere with the adhesion of microorganisms to the surfaces.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: February 27, 1996
    Assignees: Emory University, Cytrx Corporation
    Inventors: Robert L. Hunter, R. Martin Emanuele, Robert H. Carpenter
  • Patent number: RE37285
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: July 17, 2001
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE38558
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: July 20, 2004
    Assignee: CytRx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
  • Patent number: RE36665
    Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: April 18, 2000
    Assignee: Cytrx Corporation
    Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth